Original Reporting

First mRNA flu vaccine brings COVID-era concerns into flu vaccine conversations

Public discussion of mFlusiva has included substantial doubt and distrust, much of it carried over from COVID-19 vaccine conversations. Alongside that skepticism, people are asking practical questions about vaccine choice, eligibility, side effects, and access.

The story
In August 2026, the FDA approved mFlusiva, the first mRNA-based seasonal flu vaccine in the United States, for adults ages 50 and older.
The vaccine received full approval for adults ages 50–64 and accelerated approval for adults 65 and older. In a phase 3 trial involving more than 40,000 adults ages 50 and older, mFlusiva was 26.6 percent more effective at preventing laboratory-confirmed influenza illness than a licensed standard-dose flu vaccine. Moderna expects the vaccine to be available during the 2026–2027 respiratory virus season.
CONVERSATION SPIKES

What drove conversation about mRNA flu vaccines in 2026?

Conversation about the mRNA flu vaccine began well before its approval. It first spiked in February 2026, when the FDA initially refused to review Moderna’s application and reversed course a week later. Smaller spikes followed around FDA Commissioner Marty Makary’s resignation and the FDA’s vaccine advisory committee’s recommendation of the vaccine. FDA approval in August drove the largest spike in conversation. This report focuses on that period, when approval brought the vaccine to a broader public audience.

Online mentions of the mRNA flu vaccine in 2026

Select each numbered spike to see what drove the conversation.

Scroll the chart sideways to see the full period.

Conversation spikes

The FDA initially refused to review Moderna’s application for a new mRNA flu vaccine. A week later, the agency reversed course.
Weekly online mentions of the mRNA flu vaccine. Weeks run consecutively across the monitoring period; the month given for each week follows the month labels on the chart’s horizontal axis.
WeekMonthMentions

Source: Infodemiology.com analysis, 2026. Note: Weekly online mentions of the mRNA flu vaccine from December 2025 through August 2026 include social and digital media, online video platforms, news sites, blogs, forums, Q&A sites, and other web-based sources. Volume reflects posts referencing the mRNA flu vaccine or mFlusiva specifically.

QUESTIONS AND CONCERNS

What questions and concerns are people raising about the mRNA flu vaccine?

Discussion of the vaccine fell into two broad areas. Doubt and distrust were prominent, much of it rooted in skepticism about COVID-19 vaccines. Alongside these narratives, people raised practical questions about vaccine choice, eligibility, benefits, side effects, and access.

Doubts, distrust and skepticism

Longstanding doubts about the flu vaccine persisted in this conversation, including claims that the vaccine causes the flu, doesn’t work, or is unnecessary. Alongside these, familiar COVID-19 vaccine narratives resurfaced: questions and claims about shedding, genetic changes, cancer, blood clots, and cumulative harm from multiple mRNA doses.
Notably, some regular flu vaccine recipients said the introduction of an mRNA option made them less willing to receive any flu vaccine. Others worried they could receive an mRNA vaccine without knowing, particularly in mandatory vaccination settings.

Practical questions

People also raised practical questions about access, vaccine choice, eligibility, benefits, and side effects. People asked whether existing flu vaccines will remain available or eventually be phased out; why mFlusiva is approved only for adults 50 and older; whether an mRNA option will eventually become available to younger adults or other groups; how its benefits and side effects compare with existing vaccines, and whether insurance will cover it.
The approval also surfaced misconceptions about egg allergies. Some people believed an egg allergy prevents them from receiving existing flu vaccines. Current guidance says people with egg allergies can receive any age-appropriate flu vaccine, including egg-based formulations.

Common questions and concerns

The questions and concerns people raised clustered around five themes. Select a theme to explore common questions.

Eligibility and access

  • Will younger people or people at high risk from flu eventually have an mRNA option?
  • If the mRNA vaccine works, why is it only approved for adults ages 50 and older?
  • Can people with egg allergies receive existing flu vaccines, or do they need an mRNA vaccine?
  • Will insurance cover the new vaccine, and how much will it cost?
  • Is the vaccine available now?
Takeaways

What communicators can do this season

The arrival of an mRNA flu vaccine introduces a new dynamic into an already complex vaccine conversation. COVID-era mRNA concerns are appearing alongside longstanding questions about flu vaccination, while the new vaccine is also generating practical information needs around choice, eligibility, safety, and access.
These four findings can help communicators prepare for the season ahead. Select each one to see the takeaway and how to address it in messaging.
  • Lead with choice and continuity. Approval of an mRNA flu vaccine does not mean existing flu vaccines are going away. It adds another option for eligible adults where the vaccine is available. This may be particularly important for people who routinely get a flu vaccine but are uncomfortable with mRNA.
  • Make vaccine type easy to understand. Some people are worried they would not know which vaccine they are receiving, or could be required to receive an mRNA vaccine by an employer, school, or institution. Explain that multiple flu vaccine options and technologies remain available and that patients can ask a provider or pharmacist which vaccine they are being offered.
  • Continue addressing longstanding flu concerns. The mRNA conversation has not displaced questions about whether flu vaccination works, whether it can cause the flu, or whether flu is serious enough to warrant vaccination.
  • Do not let mRNA crowd out the basics. Messaging built only around mRNA leaves these older doubts unaddressed. Keep addressing them while adding information about the new mRNA option.
  • Explain what is new and what is not. mFlusiva uses mRNA rather than the approaches in existing flu vaccines, but the goal is the same: preparing the immune system to recognize influenza. Avoid framing it as replacing or fixing a problem with existing vaccines.
  • Address the age restriction. FDA approval currently applies only to adults 50 and older. That age indication should not be interpreted, on its own, as evidence that the vaccine is unsafe for younger people.
  • Clarify egg allergy guidance. People with egg allergies do not need to wait for an mRNA vaccine. Current guidance says they can receive any age-appropriate flu vaccine, including egg-based ones.
  • Focus on the questions that can change decisions. Proactively address choice, eligibility, safety, side effects, and benefits rather than repeating and rebutting every false claim individually.
  • Put trial findings in context. Some claims may point to higher rates of “adverse events” without distinguishing common short-term reactions from serious adverse events. Explain that reactions such as injection-site pain, fatigue, headache, and muscle aches occurred more often with mFlusiva, while serious adverse events occurred at similar rates in the trial groups.